# Congressional Researchers Provide Update on Marijuana Rescheduling and Hemp Policy > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/marijuana-rescheduling-federal-research-update/ > **Published:** 2026-03-17T09:26:56-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:58:17-04:00 > **Clinical Summary:** Explore the latest on marijuana rescheduling federal research and its impact on clinical practice and cannabis policy developments. --- ✦ New CED Clinical Relevance #65 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchHemp Clinical Summary # Clinical Summary Congressional research indicates ongoing deliberation regarding marijuana rescheduling at the federal level, with implications for research accessibility and [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/) standards. Currently, state-level [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) does not alter marijuana’s federal Schedule I classification, which continues to restrict federally-funded research and complicates [clinical evidence](https://cedclinic.com/academic-partnerships-cannabis-research/) generation for therapeutic applications. The rescheduling discussion reflects growing recognition that current federal restrictions impede rigorous clinical investigation into cannabis efficacy and safety profiles for various patient populations. Changes to federal scheduling could expand the research infrastructure available to clinicians and accelerate the development of evidence-based dosing, [drug interaction](https://cedclinic.com/glp-1-addiction-risk-reduction-benefits/) data, and indications comparable to other pharmaceutical agents. For clinicians managing patients in states where cannabis is legal, federal rescheduling would potentially improve access to standardized products, clinical trial participation opportunities, and reliable safety data to inform prescribing decisions. Clinicians should monitor federal regulatory changes as they will significantly impact the quality of evidence available to support cannabis-based treatment recommendations in clinical practice. Dr. Caplan’s Take “The federal scheduling of cannabis remains our biggest clinical obstacle, not because the science is unclear, but because the bureaucratic framework prevents us from conducting the rigorous trials that would actually inform our prescribing decisions.” Clinical Perspective Recent congressional updates on marijuana rescheduling highlight a persistent disconnect between state-level legalization and federal regulatory frameworks that continues to complicate clinical practice. While nearly two-thirds of U.S. states have legalized cannabis for medical or recreational use, its Schedule I status federally restricts research, complicates prescribing, and creates liability concerns for healthcare providers who document patient use or consider cannabis in treatment plans. Clinicians should recognize that patients may access cannabis legally under state law while remaining unable to obtain consistent dosing, quality assurance, or clinical evidence comparable to FDA-approved medications. Until federal policy changes materialize, practitioners should maintain open, non-judgmental conversations about patient [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/), document decisions transparently, and understand that state legal status does not resolve federal regulatory or clinical evidence gaps. In the interim, staying informed about evolving policy discussions helps providers better counsel patients on risks, benefits, and alternative options while advocating for 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Congressional+Researchers+Give+Update+On+Marijuana+Rescheduling+And+Upcoming+Hemp+...+%40drcaplan&url=https%3A%2F%2Fwww.marijuanamoment.net%2Fcongressional-researchers-give-update-on-marijuana-rescheduling-and-upcoming-hemp-thc-ban%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.marijuanamoment.net%2Fcongressional-researchers-give-update-on-marijuana-rescheduling-and-upcoming-hemp-thc-ban%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Congressional+Researchers+Give+Update+On+Marijuana+Rescheduling+And+Upcoming+Hemp+...+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.marijuanamoment.net%2Fcongressional-researchers-give-update-on-marijuana-rescheduling-and-upcoming-hemp-thc-ban%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [CED Digest: 230 Items — March 15, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-clinical-relevance-2026/) - [CED Digest: 436 Items — March 14, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 405 Items — March 12, 2026](https://cedclinic.com/alabama-medical-cannabis-sales-2026-spring-launch/) 📰 Source: [https://www.marijuanamoment.net/congressional-researchers-give-update-on-marijuana-rescheduling-and-upcoming-hemp-thc-ban/](https://www.marijuanamoment.net/congressional-researchers-give-update-on-marijuana-rescheduling-and-upcoming-hemp-thc-ban/) Further Reading CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) Evidence Watch[Cannabinoid Clinical Trials: CBD Cortical Excitability Study](https://cedclinic.com/cannabidiol-lacks-intrinsic-anti-epileptic-properties-trial/) Research Digest[AM Policy Update: March 17, 2026](https://cedclinic.com/dea-synthetic-opioids-schedule-i-march-17-2026/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Trump ready to move on cannabis rescheduling (Newsletter: April 23, 2026)](https://cedclinic.com/cannabis-federal-rescheduling-clinical-implications/) Insights on the Trump administration's stance and actions regarding cannabis rescheduling efforts. [Read More](https://cedclinic.com/cannabis-federal-rescheduling-clinical-implications/) [The right schedule for marijuana (among other drugs) does not yet exist | Science](https://cedclinic.com/2026-cannabis-schedule-classification-challenges/) Scientific perspectives on the challenges of appropriately scheduling marijuana within federal regulations. [Explore Article](https://cedclinic.com/2026-cannabis-schedule-classification-challenges/) [New Congressional Bill Would Let State Agencies Provide Marijuana For Research, Backed …](https://cedclinic.com/new-congressional-bill-marijuana-research-access/) Details on legislative efforts to facilitate marijuana research through state agency involvement. [Learn More](https://cedclinic.com/new-congressional-bill-marijuana-research-access/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).